Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

Ankit X. Sharma, Ezekiel B. Quittner-Strom, Young H Lee, Joshua A. Johnson, Sarah A. Martin, Xinxin Yu, Jianping Li, John Lu, Zheqing Cai, Shiuhwei Chen, May-Yun Wang, Yiyi Zhang, Mackenzie J. Pearson, Andie C. Dorn, Jeffrey G McDonald, Ruth Gordillo, Hai Yan, Dung Thai, Zhao Wang, Roger H UngerWilliam L Holland

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Leprdb/db and Lepob/ob mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor. As expected, REMD 2.59 suppresses hepatic glucose production and improves glycemia. Surprisingly, it also enhances insulin action in both liver and skeletal muscle, coinciding with an increase in AMP-activated protein kinase (AMPK)-mediated lipid oxidation. Furthermore, weekly REMD 2.59 treatment over a period of months protects against diabetic cardiomyopathy. These functional improvements are not derived simply from correcting the systemic milieu; nondiabetic mice with cardiac-specific overexpression of lipoprotein lipase also show improvements in contractile function after REMD 2.59 treatment. These observations suggest that hyperglucagonemia enables lipotoxic conditions, allowing the development of insulin resistance and cardiac dysfunction during disease progression. Sharma et al. highlight the regulatory roles for glucagon in managing type 2 diabetes and diabetic cardiomyopathy. REMD 2.59 is a fully humanized antibody that competitively inhibits glucagon receptor signaling, increasing lipid oxidation in liver, skeletal muscle, and heart and improving whole-body insulin sensitivity and cardiac function.

Original languageEnglish (US)
Pages (from-to)1760-1773
Number of pages14
JournalCell Reports
Volume22
Issue number7
DOIs
StatePublished - Feb 13 2018

Fingerprint

Glucagon Receptors
Adenosine Monophosphate
Metabolism
Protein Kinases
Diabetic Cardiomyopathies
Insulin
Glucose
Medical problems
Liver
Type 2 Diabetes Mellitus
Muscle
Insulin Resistance
Skeletal Muscle
Lipids
Antibodies, Monoclonal, Humanized
Oxidation
AMP-Activated Protein Kinases
Lipoprotein Lipase
Glucagon
Hypoglycemic Agents

Keywords

  • adiponectin
  • ceramide
  • lipotoxicity
  • sphingolipid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice. / Sharma, Ankit X.; Quittner-Strom, Ezekiel B.; Lee, Young H; Johnson, Joshua A.; Martin, Sarah A.; Yu, Xinxin; Li, Jianping; Lu, John; Cai, Zheqing; Chen, Shiuhwei; Wang, May-Yun; Zhang, Yiyi; Pearson, Mackenzie J.; Dorn, Andie C.; McDonald, Jeffrey G; Gordillo, Ruth; Yan, Hai; Thai, Dung; Wang, Zhao; Unger, Roger H; Holland, William L.

In: Cell Reports, Vol. 22, No. 7, 13.02.2018, p. 1760-1773.

Research output: Contribution to journalArticle

Sharma, AX, Quittner-Strom, EB, Lee, YH, Johnson, JA, Martin, SA, Yu, X, Li, J, Lu, J, Cai, Z, Chen, S, Wang, M-Y, Zhang, Y, Pearson, MJ, Dorn, AC, McDonald, JG, Gordillo, R, Yan, H, Thai, D, Wang, Z, Unger, RH & Holland, WL 2018, 'Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice', Cell Reports, vol. 22, no. 7, pp. 1760-1773. https://doi.org/10.1016/j.celrep.2018.01.065
Sharma, Ankit X. ; Quittner-Strom, Ezekiel B. ; Lee, Young H ; Johnson, Joshua A. ; Martin, Sarah A. ; Yu, Xinxin ; Li, Jianping ; Lu, John ; Cai, Zheqing ; Chen, Shiuhwei ; Wang, May-Yun ; Zhang, Yiyi ; Pearson, Mackenzie J. ; Dorn, Andie C. ; McDonald, Jeffrey G ; Gordillo, Ruth ; Yan, Hai ; Thai, Dung ; Wang, Zhao ; Unger, Roger H ; Holland, William L. / Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice. In: Cell Reports. 2018 ; Vol. 22, No. 7. pp. 1760-1773.
@article{4983c69c2abb4dd5a7f0bd32154213af,
title = "Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice",
abstract = "The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Leprdb/db and Lepob/ob mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor. As expected, REMD 2.59 suppresses hepatic glucose production and improves glycemia. Surprisingly, it also enhances insulin action in both liver and skeletal muscle, coinciding with an increase in AMP-activated protein kinase (AMPK)-mediated lipid oxidation. Furthermore, weekly REMD 2.59 treatment over a period of months protects against diabetic cardiomyopathy. These functional improvements are not derived simply from correcting the systemic milieu; nondiabetic mice with cardiac-specific overexpression of lipoprotein lipase also show improvements in contractile function after REMD 2.59 treatment. These observations suggest that hyperglucagonemia enables lipotoxic conditions, allowing the development of insulin resistance and cardiac dysfunction during disease progression. Sharma et al. highlight the regulatory roles for glucagon in managing type 2 diabetes and diabetic cardiomyopathy. REMD 2.59 is a fully humanized antibody that competitively inhibits glucagon receptor signaling, increasing lipid oxidation in liver, skeletal muscle, and heart and improving whole-body insulin sensitivity and cardiac function.",
keywords = "adiponectin, ceramide, lipotoxicity, sphingolipid",
author = "Sharma, {Ankit X.} and Quittner-Strom, {Ezekiel B.} and Lee, {Young H} and Johnson, {Joshua A.} and Martin, {Sarah A.} and Xinxin Yu and Jianping Li and John Lu and Zheqing Cai and Shiuhwei Chen and May-Yun Wang and Yiyi Zhang and Pearson, {Mackenzie J.} and Dorn, {Andie C.} and McDonald, {Jeffrey G} and Ruth Gordillo and Hai Yan and Dung Thai and Zhao Wang and Unger, {Roger H} and Holland, {William L}",
year = "2018",
month = "2",
day = "13",
doi = "10.1016/j.celrep.2018.01.065",
language = "English (US)",
volume = "22",
pages = "1760--1773",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "7",

}

TY - JOUR

T1 - Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

AU - Sharma, Ankit X.

AU - Quittner-Strom, Ezekiel B.

AU - Lee, Young H

AU - Johnson, Joshua A.

AU - Martin, Sarah A.

AU - Yu, Xinxin

AU - Li, Jianping

AU - Lu, John

AU - Cai, Zheqing

AU - Chen, Shiuhwei

AU - Wang, May-Yun

AU - Zhang, Yiyi

AU - Pearson, Mackenzie J.

AU - Dorn, Andie C.

AU - McDonald, Jeffrey G

AU - Gordillo, Ruth

AU - Yan, Hai

AU - Thai, Dung

AU - Wang, Zhao

AU - Unger, Roger H

AU - Holland, William L

PY - 2018/2/13

Y1 - 2018/2/13

N2 - The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Leprdb/db and Lepob/ob mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor. As expected, REMD 2.59 suppresses hepatic glucose production and improves glycemia. Surprisingly, it also enhances insulin action in both liver and skeletal muscle, coinciding with an increase in AMP-activated protein kinase (AMPK)-mediated lipid oxidation. Furthermore, weekly REMD 2.59 treatment over a period of months protects against diabetic cardiomyopathy. These functional improvements are not derived simply from correcting the systemic milieu; nondiabetic mice with cardiac-specific overexpression of lipoprotein lipase also show improvements in contractile function after REMD 2.59 treatment. These observations suggest that hyperglucagonemia enables lipotoxic conditions, allowing the development of insulin resistance and cardiac dysfunction during disease progression. Sharma et al. highlight the regulatory roles for glucagon in managing type 2 diabetes and diabetic cardiomyopathy. REMD 2.59 is a fully humanized antibody that competitively inhibits glucagon receptor signaling, increasing lipid oxidation in liver, skeletal muscle, and heart and improving whole-body insulin sensitivity and cardiac function.

AB - The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Leprdb/db and Lepob/ob mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor. As expected, REMD 2.59 suppresses hepatic glucose production and improves glycemia. Surprisingly, it also enhances insulin action in both liver and skeletal muscle, coinciding with an increase in AMP-activated protein kinase (AMPK)-mediated lipid oxidation. Furthermore, weekly REMD 2.59 treatment over a period of months protects against diabetic cardiomyopathy. These functional improvements are not derived simply from correcting the systemic milieu; nondiabetic mice with cardiac-specific overexpression of lipoprotein lipase also show improvements in contractile function after REMD 2.59 treatment. These observations suggest that hyperglucagonemia enables lipotoxic conditions, allowing the development of insulin resistance and cardiac dysfunction during disease progression. Sharma et al. highlight the regulatory roles for glucagon in managing type 2 diabetes and diabetic cardiomyopathy. REMD 2.59 is a fully humanized antibody that competitively inhibits glucagon receptor signaling, increasing lipid oxidation in liver, skeletal muscle, and heart and improving whole-body insulin sensitivity and cardiac function.

KW - adiponectin

KW - ceramide

KW - lipotoxicity

KW - sphingolipid

UR - http://www.scopus.com/inward/record.url?scp=85042041851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042041851&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.01.065

DO - 10.1016/j.celrep.2018.01.065

M3 - Article

C2 - 29444429

AN - SCOPUS:85042041851

VL - 22

SP - 1760

EP - 1773

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 7

ER -